Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EML4-ALK fusion
i
Other names:
EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
;
27436
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK rearrangement (43)
ALK mutation (20)
ALK wild-type (18)
STRN-ALK rearrangement (10)
ALK translocation (9)
ALK F1174L (7)
ALK G1202R (7)
ALK C1156Y (6)
EGFR wild-type + ALK wild-type (6)
ALK A348D (5)
ALK F856S (5)
EML4-ALK rearrangement (5)
ALK G1202del (4)
ALK G1269A (4)
ALK I1171N (4)
ALK I1171T (4)
ALK rearrangement + TP53 mutation (4)
ALK F1174C (3)
ALK F1174V (3)
ALK F1245C (3)
ALK G1202K (3)
ALK I1171 (3)
ALK L1196M (3)
ALK R1275Q (3)
TYRO3 mutation + ALK mutation (3)
ALK C1156Y + ALK I1171T (2)
ALK C1156Y + ALK L1198F (2)
ALK E1210K (2)
ALK F1174L + ALK G1202R (2)
ALK I1171S (2)
ALK L1152R (2)
ALK L1198F (2)
ALK S1206Y (2)
ALK V1180L (2)
ALK V3a (2)
ALK V3b (2)
DCTN1-ALK rearrangement + ALK-CLIP4 rearrangement (2)
ALK C1156F (1)
ALK C1156Y + ALK G1202R (1)
ALK D1091N (1)
ALK D1203N (1)
ALK E1129V (1)
ALK F1174I (1)
ALK G1123S (1)
ALK G1128A (1)
ALK G1202L (1)
ALK G1202R + ALK F1174L + ALK T1151M (1)
ALK I1268L (1)
ALK L1152R + EGFR mutation (1)
ALK L1152V (1)
ALK L1196M + ALK C1156Y (1)
ALK L1196M + ALK G1202R (1)
ALK L1196M + ALK L1198F (1)
ALK L1198F + ALK G1202R (1)
ALK R1192P (1)
ALK R1209Q (1)
ALK R1231W (1)
ALK R214H (1)
ALK S1157F (1)
ALK T1151M (1)
ALK T1151R (1)
ALK TKD mutation (1)
ALK rearrangement + ALK L1196M + TP53 mutation (1)
ALK rearrangement + ALK R1275Q + TP53 mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + HER-2 mutation (1)
ALK rearrangement + KRAS mutation (1)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
ALK rearrangement + TP53 wild-type (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR mutation + ALK mutation (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EML4-ALK I1171N + EML4-ALK L1196M (1)
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R (1)
LMO7-ALK rearrangement (1)
PLEKHH2-ALK rearrangement (1)
RMST-ALK rearrangement (1)
TP53 G245S + ALK rearrangement (1)
EML4-NTRK3 rearrangement (1)
ALK mutation + TP53 mutation (0)
ALK rearrangement (43)
ALK mutation (20)
ALK wild-type (18)
STRN-ALK rearrangement (10)
ALK translocation (9)
ALK F1174L (7)
ALK G1202R (7)
ALK C1156Y (6)
EGFR wild-type + ALK wild-type (6)
ALK A348D (5)
ALK F856S (5)
EML4-ALK rearrangement (5)
ALK G1202del (4)
ALK G1269A (4)
ALK I1171N (4)
ALK I1171T (4)
ALK rearrangement + TP53 mutation (4)
ALK F1174C (3)
ALK F1174V (3)
ALK F1245C (3)
ALK G1202K (3)
ALK I1171 (3)
ALK L1196M (3)
ALK R1275Q (3)
TYRO3 mutation + ALK mutation (3)
ALK C1156Y + ALK I1171T (2)
ALK C1156Y + ALK L1198F (2)
ALK E1210K (2)
ALK F1174L + ALK G1202R (2)
ALK I1171S (2)
ALK L1152R (2)
ALK L1198F (2)
ALK S1206Y (2)
ALK V1180L (2)
ALK V3a (2)
ALK V3b (2)
DCTN1-ALK rearrangement + ALK-CLIP4 rearrangement (2)
ALK C1156F (1)
ALK C1156Y + ALK G1202R (1)
ALK D1091N (1)
ALK D1203N (1)
ALK E1129V (1)
ALK F1174I (1)
ALK G1123S (1)
ALK G1128A (1)
ALK G1202L (1)
ALK G1202R + ALK F1174L + ALK T1151M (1)
ALK I1268L (1)
ALK L1152R + EGFR mutation (1)
ALK L1152V (1)
ALK L1196M + ALK C1156Y (1)
ALK L1196M + ALK G1202R (1)
ALK L1196M + ALK L1198F (1)
ALK L1198F + ALK G1202R (1)
ALK R1192P (1)
ALK R1209Q (1)
ALK R1231W (1)
ALK R214H (1)
ALK S1157F (1)
ALK T1151M (1)
ALK T1151R (1)
ALK TKD mutation (1)
ALK rearrangement + ALK L1196M + TP53 mutation (1)
ALK rearrangement + ALK R1275Q + TP53 mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + HER-2 mutation (1)
ALK rearrangement + KRAS mutation (1)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
ALK rearrangement + TP53 wild-type (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR mutation + ALK mutation (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EML4-ALK I1171N + EML4-ALK L1196M (1)
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R (1)
LMO7-ALK rearrangement (1)
PLEKHH2-ALK rearrangement (1)
RMST-ALK rearrangement (1)
TP53 G245S + ALK rearrangement (1)
EML4-NTRK3 rearrangement (1)
ALK mutation + TP53 mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
crizotinib
Resistant: C2 – Inclusion Criteria
crizotinib
Resistant
:
C2
crizotinib
Resistant: C2 – Inclusion Criteria
crizotinib
Resistant
:
C2
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
Tyrosine kinase inhibitor
Resistant
:
C3
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
Tyrosine kinase inhibitor
Resistant
:
C3
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
EML4-ALK fusion
Ovarian Cancer
EML4-ALK fusion
Ovarian Cancer
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
EML4-ALK fusion
Breast Cancer
EML4-ALK fusion
Breast Cancer
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
GC
Resistant: C4 – Case Studies
GC
Resistant
:
C4
GC
Resistant: C4 – Case Studies
GC
Resistant
:
C4
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C4 – Case Studies
brigatinib
Sensitive
:
C4
brigatinib
Sensitive: C4 – Case Studies
brigatinib
Sensitive
:
C4
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
EML4-ALK fusion
Neuroendocrine Tumor
EML4-ALK fusion
Neuroendocrine Tumor
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
atezolizumab
Sensitive: C4 – Case Studies
atezolizumab
Sensitive
:
C4
atezolizumab
Sensitive: C4 – Case Studies
atezolizumab
Sensitive
:
C4
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
EML4-ALK fusion
Neuroendocrine Tumor
EML4-ALK fusion
Neuroendocrine Tumor
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
ensartinib
Sensitive: C4 – Case Studies
ensartinib
Sensitive
:
C4
ensartinib
Sensitive: C4 – Case Studies
ensartinib
Sensitive
:
C4
EML4-ALK fusion
Salivary Gland Cancer
EML4-ALK fusion
Salivary Gland Cancer
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C4 – Case Studies
Immunotherapy
Sensitive
:
C4
Immunotherapy
Sensitive: C4 – Case Studies
Immunotherapy
Sensitive
:
C4
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
lorlatinib
Sensitive: C4 – Case Studies
lorlatinib
Sensitive
:
C4
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
MTI-31
Sensitive: D – Preclinical
MTI-31
Sensitive
:
D
MTI-31
Sensitive: D – Preclinical
MTI-31
Sensitive
:
D
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
ADX-1612
Sensitive: D – Preclinical
ADX-1612
Sensitive
:
D
ADX-1612
Sensitive: D – Preclinical
ADX-1612
Sensitive
:
D
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
ceritinib + U0126
Sensitive: D – Preclinical
ceritinib + U0126
Sensitive
:
D
ceritinib + U0126
Sensitive: D – Preclinical
ceritinib + U0126
Sensitive
:
D
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
lorlatinib
Resistant: D – Preclinical
lorlatinib
Resistant
:
D
lorlatinib
Resistant: D – Preclinical
lorlatinib
Resistant
:
D
EML4-ALK fusion
Melanoma
EML4-ALK fusion
Melanoma
crizotinib
Sensitive: D – Preclinical
crizotinib
Sensitive
:
D
crizotinib
Sensitive: D – Preclinical
crizotinib
Sensitive
:
D
EML4-ALK fusion
Melanoma
EML4-ALK fusion
Melanoma
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
EML4-ALK fusion
Non Small Cell Lung Cancer
EML4-ALK fusion
Non Small Cell Lung Cancer
gilteritinib
Sensitive: D – Preclinical
gilteritinib
Sensitive
:
D
gilteritinib
Sensitive: D – Preclinical
gilteritinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login